PDS Biotechnology
PDSB
41 hedge funds and large institutions have $3.05M invested in PDS Biotechnology in 2026 Q1 according to their latest regulatory filings, with 7 funds opening new positions, 11 increasing their positions, 9 reducing their positions, and 9 closing their positions.
22% more repeat investments, than reductions
Existing positions increased: 11 | Existing positions reduced: 9
6.45% less ownership
Funds ownership: 16.09% → 9.64% (-6.5%)
7% less funds holding
Funds holding: 44 → 41 (-3)
22% less first-time investments, than exits
New positions opened: 7 | Existing positions closed: 9
50% less capital invested
Capital invested by funds: $6.07M → $3.05M (-$3.01M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Geode Capital Management
Boston,
Massachusetts
|
+$105K |
| 2 |
Wells Fargo
San Francisco,
California
|
+$79.1K |
| 3 |
NMC
Nine Masts Capital
Central,
Hong Kong
|
+$50.8K |
| 4 |
William Blair & Company
Chicago,
Illinois
|
+$37.6K |
| 5 |
Renaissance Technologies
New York
|
+$33.2K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AC
Armistice Capital
New York
|
-$2M |
| 2 |
Squarepoint
New York
|
-$148K |
| 3 |
UBS Group
Zurich,
Switzerland
|
-$147K |
| 4 |
Commonwealth Equity Services
Waltham,
Massachusetts
|
-$79.7K |
| 5 |
Northern Trust
Chicago,
Illinois
|
-$26.3K |
PDSB Hedge Fund Activity: Q1 2026 in Review
41 of the 8,191 institutional investors tracked by Wall St. Rank reported a position in PDS Biotechnology (PDSB) for Q1 2026, worth a combined $3.05M — down 50% from $6.07M a quarter earlier.
Sellers outnumbered buyers: 9 funds closed out of PDSB and 7 opened new positions — a net loss of 2 holders — while 9 trimmed existing stakes and 11 added.
The largest buyer was Geode Capital Management, adding an estimated $105K. The largest seller was Armistice Capital, cutting an estimated $2M.
- 41 institutional investors held PDS Biotechnology (PDSB) as of Q1 2026, down from 44 in Q4 2025.
- Funds reported $3.05M of PDS Biotechnology stock for Q1 2026, down 50% quarter-over-quarter.
- 7 funds opened new PDS Biotechnology positions in Q1 2026 and 9 closed out, a net change of -2 holders.
- The largest PDS Biotechnology buyer in Q1 2026 was Geode Capital Management, an estimated $105K added.
- The largest PDS Biotechnology seller in Q1 2026 was Armistice Capital, an estimated $2M sold.
Based on aggregated 13F filings for Q1 2026.